건강보험청구데이터를 이용하여 사용상의 주의사항에 자살이 기재된 약물의 처방 양상 분석
Analysis of the Prescription Patterns of Medications that List Suicide in Use Cautions using the HIRA Claims Data
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Suicide has recently become an important social problem. Thus, we analyzed prescription drugs that cause suicidal ideation. Methods: Of 156 drugs on the the Minister of Food and Drug Safty (MFDS) EZ-Drug site that had “suicide” listed as a side effect, 78 had “suicide” listed as a warning or contraindication; those 78 drugs were analyzed using data from the 2016 Health Insurance and Review and Assessment Services National Patient Sample (HIRA-NPS). Results: 51 “suicide risk” drugs was identified. Of all patients, 5.2% had received such drugs. The prescription rate was 0.8% of all prescriptions, accounting for 1.6% of all prescription days. From logistic regression analysis, the prescription rate for the drugs was approximately 1.1 times higher for women than for men. With regard to age, the prescription rate for patients 66 years and older was 15.5 times higher than those for patients 25-years and lower. With regard to medical departments, the prescription rates in psychiatry and dermatology departments were 8.1 times higher and 0.6 times lower than those in internal medicine departments, respectively. With regard to region, the prescription rates in Daegu and Jeju were 1.3 times higher and 0.79 times lower than those in Seoul, respectively. Conclusion:Drug-induced suicidal behavior is possible, and therefore efforts are needed to prevent it.
Abstract
Objective: Suicide has recently become an important social problem. Thus, we analyzed prescription drugs that cause suicidal ideation. Methods: Of 156 drugs on the the Minister of Food and Drug Safty (MFDS) EZ-Drug site that had “suicide” listed as a side effect, 78 had “suicide” listed as a warning or contraindication; those 78 drugs were analyzed using data from the 2016 Health Insurance and Review and Assessment Services National Patient Sample (HIRA-NPS). Results: 51 “suicide risk” drugs was identified. Of all patients, 5.2% had received such drugs. The prescription rate was 0.8% of all prescriptions, accounting for 1.6% of all prescription days. From logistic regression analysis, the prescription rate for the drugs was approximately 1.1 times higher for women than for men. With regard to age, the prescription rate for patients 66 years and older was 15.5 times higher than those for patients 25-years and lower. With regard to medical departments, the prescription rates in psychiatry and dermatology departments were 8.1 times higher and 0.6 times lower than those in internal medicine departments, respectively. With regard to region, the prescription rates in Daegu and Jeju were 1.3 times higher and 0.79 times lower than those in Seoul, respectively. Conclusion:Drug-induced suicidal behavior is possible, and therefore efforts are needed to prevent it.
참고문헌 (17)
- "Statistics of causes of death in 2016"[URL]
- "36 people a day, 1 person every 40 minutes suicide country ... 13th year OECD 1st place"[URL]
- "Korea’s suicide rate is 25.8 per 100,000 people in 2016…No. 1 in the OECD despite the decline"[URL]
- "Suicide prevention national action plan"[URL]
- Olfson M, "Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study", Archives of General Psychiatry, 63(8), pp.865~872 (2006)
- "2015~2018.6 Report status of abnormalities by substance (suicide, suicidal tendencies, suicide attempts)" (2018)[URL]
- Takeuchi T, "The relationship between psychotropic drug use and suicidal behavior in Japan: Japanese adverse drug event report", Pharmacopsychiatry, 50(2), pp.69~73 (2017)
- Bell GS, "Suicidality in people taking antiepileptic drugs: What is the evidence?", CNS Drugs, 23(4), pp.281~292 (2009)
- Ministry of Health and Welfare, "Suicide prevention white paper", pp.1~170 (2017)
- Bangs ME, "Meta-analysis of suicide-related behavior events in patients treated with atomoxetine", J Am Acad Child Adolesc Psychiatry, 47(2), pp.209~218 (2008)
- Beasley CM Jr, "Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials", J Clin Psychopharmacol, 27(6), pp.682~686 (2007)
- Kölch M, "Medical treatment of depression in hilderen and adolescents", Prax Kinderpsychol Kinderpsychiatr, 56(3), pp.224~233 (2007)
- Pedersen AG, "Citalopram and suicidality in adult major depression and anxiety disorders", Nord J psychiatry, 60(5), pp.392~399 (2006)
- Poole-Wilson PA, "Safety of nifedipine GITS in stable angina: the ACTION trial", Cardiocasc Drugs Ther, 20(1), pp.45~54 (2006)
- Maglione M, "Psychatric symptoms associated with ephedra use", Expert Opin Drug Saf, 4(5), pp.879~884 (2005)
- Wolf DV, "Sucidality following black-box warning", J Am Acad Child Adolesc Psychiatry, 44(5), pp.405~ (2005)
- Brent DA, "Antidepressants and pediatric depression -- the risk of doing nothing", N Engl J Med, 351(16), pp.1598~1601 (2004)